COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlThomas (RCT)12%0.88 [0.39-1.99]recov. time5850Asimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Tau​2 = 1.92; I​2 = 69.7%Early treatment76%0.24 [0.04-1.63]1/46922/51376% improvementCarlucci38%0.62 [0.45-0.86]death/HPC411521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera37%0.63 [0.44-0.91]death121/1,006424/2,467Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Al Sulaiman35%0.65 [0.41-1.01]death35/13045/129Tau​2 = 0.00; I​2 = 0.0%Late treatment33%0.67 [0.59-0.76]265/1,897556/3,35233% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP100%0.00 [0.00-0.93]0/106,953/20,849100% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Berrocal45%0.55 [0.23-1.31]death5/3126/89Tau​2 = 0.88; I​2 = 51.6%Sufficiency78%0.22 [0.05-0.96]6/7137/12578% improvementAll studies47%0.53 [0.39-0.72]305/3,0817,632/25,45847% improvement14 zinc COVID-19 studiesc19zinc.com 7/30/211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.18; I​2 = 76.2%; Z = 3.98 (p < 0.0001)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]1/14113/377Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.03-1.47]1/14113/37779% improvementKrishnan18%0.82 [0.62-1.09]31/5861/94Improvement, RR [CI]TreatmentControlYao34%0.66 [0.41-1.07]73/19621/46Frontera37%0.63 [0.44-0.91]121/1,006424/2,467Abd-Elsalam (RCT)1%0.99 [0.30-3.31]5/965/95Al Sulaiman35%0.65 [0.41-1.01]35/13045/129Tau​2 = 0.00; I​2 = 0.0%Late treatment32%0.68 [0.59-0.78]265/1,486556/2,83132% improvementJothimani90%0.10 [0.01-1.76]0/205/27Improvement, RR [CI]TreatmentControlBerrocal45%0.55 [0.23-1.31]5/3126/89Tau​2 = 0.26; I​2 = 18.6%Sufficiency58%0.42 [0.13-1.41]5/5131/11658% improvementAll studies33%0.67 [0.59-0.76]271/1,678600/3,32433% improvement8 zinc COVID-19 mortality resultsc19zinc.com 7/30/21Tau​2 = 0.00; I​2 = 0.0%; Z = 5.98 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Jothimani92%0.08 [0.00-1.26]0/207/27Improvement, RR [CI]TreatmentControlBerrocal53%0.47 [0.26-0.83]9/3155/89Tau​2 = 0.59; I​2 = 35.8%Sufficiency68%0.32 [0.08-1.37]9/5162/11668% improvementAll studies68%0.32 [0.08-1.37]9/5162/11668% improvement2 zinc COVID-19 ICU resultsc19zinc.com 7/30/21Tau​2 = 0.59; I​2 = 35.8%; Z = 1.53 (p = 0.063)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand82%0.18 [0.07-0.54]hosp.4/14158/377Improvement, RR [CI]TreatmentControlAsimi99%0.01 [0.00-0.16]hosp.0/27024/86CT​1Tau​2 = 3.11; I​2 = 73.1%Early treatment94%0.06 [0.00-0.95]4/41182/46394% improvementAbd-Elsalam (RCT)4%0.96 [0.57-1.65]hosp. time9695Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment4%0.96 [0.57-1.65]0/960/954% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP100%0.00 [0.00-0.93]0/106,953/20,849100% improvementAll studies97%0.03 [0.00-0.46]4/5177,035/21,40797% improvement4 zinc COVID-19 hospitalization resultsc19zinc.com 7/30/211 CT: study uses combined treatmentTau​2 = 6.36; I​2 = 94.2%; Z = 2.54 (p = 0.0056)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Seet (CLUS. RCT)27%0.73 [0.41-1.05]300/634433/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP27%0.73 [0.41-1.05]300/634433/61927% improvementAll studies27%0.73 [0.66-0.81]300/634433/61927% improvement1 zinc COVID-19 case resultc19zinc.com 7/30/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 6.32 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Yasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Berrocal45%0.55 [0.23-1.31]death5/3126/89All studies78%0.22 [0.05-0.96]6/7137/12578% improvement3 zinc COVID-19 sufficiency studiesc19zinc.com 7/30/21Tau​2 = 0.88; I​2 = 51.6%; Z = 2.01 (p = 0.022)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlAsimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Tau​2 = 0.55; I​2 = 25.8%Early treatment91%0.09 [0.01-0.67]1/41122/46391% improvementCarlucci38%0.62 [0.45-0.86]death/HPC411521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera37%0.63 [0.44-0.91]death121/1,006424/2,467Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Al Sulaiman35%0.65 [0.41-1.01]death35/13045/129Tau​2 = 0.00; I​2 = 0.0%Late treatment33%0.67 [0.59-0.76]265/1,897556/3,35233% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP100%0.00 [0.00-0.93]0/106,953/20,849100% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Berrocal45%0.55 [0.23-1.31]death5/3126/89Tau​2 = 0.88; I​2 = 51.6%Sufficiency78%0.22 [0.05-0.96]6/7137/12578% improvementAll studies49%0.51 [0.36-0.70]305/3,0237,632/25,40849% improvement13 zinc COVID-19 serious outcomesc19zinc.com 7/30/211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.19; I​2 = 77.7%; Z = 4.05 (p < 0.0001)Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand79%0.21 [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlDerwand82%0.18 [0.07-0.54]hosp.4/14158/377Thomas (RCT)12%0.88 [0.39-1.99]recov. time5850Asimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Asimi99%0.01 [0.00-0.16]hosp.0/27024/86CT​2Asimi100%0.00 [0.00-0.08]severe case0/27051/86CT​2Carlucci38%0.62 [0.45-0.86]death/HPC411521Krishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera37%0.63 [0.44-0.91]death121/1,006424/2,467Frontera24%0.76 [0.60-0.96]death121/1,006424/2,467Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Abd-Elsalam (RCT)34%0.66 [0.19-2.26]ventilation4/966/95Abd-Elsalam (RCT)6%0.94 [0.55-1.62]no recov.20/9621/95Abd-Elsalam (RCT)4%0.96 [0.57-1.65]hosp. time9695Al Sulaiman35%0.65 [0.41-1.01]death35/13045/129Al Sulaiman23%0.77 [0.34-1.73]ventilation20/5723/54Israel100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Seet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Seet (CLUS. RCT)27%0.73 [0.41-1.05]cases300/634433/619OT​1Yasui92%0.07 [0.01-0.54]ventilation1/206/9Jothimani90%0.10 [0.01-1.76]death0/205/27Jothimani92%0.08 [0.00-1.26]ICU0/207/27Berrocal45%0.55 [0.23-1.31]death5/3126/89Berrocal53%0.47 [0.26-0.83]ICU9/3155/89zinc COVID-19 outcomesc19zinc.com 7/30/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit